Uncover Disease Pathophysiology, Clarify Response Biomarkers, Leverage Electronic Health Records & Implement Patient-Centric Recruitment Strategies to Accelerate Game-Changing Therapies to Patients

Welcome to the 4th Rare & Genetic Kidney Disease Drug Development Summit

With recent accelerated approval wins, positive clinical trial readouts, progression through clinical pipelines and exciting mergers and acquisitions, it has certainly been an industry-defining year for the rare and genetic renal space.

In the context of rapid progress and a mounting desire to propel game-changing novel therapies that will add to the arsenal of therapeutic options for patients, the 4th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston. This unique event for the industry, academic KOL, and patient advocacy nephrology community provides an unrivalled opportunity to discuss acceleration of clinical advancements in orphan kidney disease populations.

This year’s meeting brings together 30+ expert speakers, a two-tracked pre-conference workshop day and new content on podocyte biology, tissue bioengineering of kidney tissue models, market access strategies, as well as pricing and reimbursement conversations, across a breadth of rare renal therapeutic areas including FSGS, PKD, Alport Syndrome and IgAN to name but a few!

The 4th Rare & Genetic Kidney Disease Drug Development Summit is your most comprehensive opportunity for learning about the latest preclinical and clinical progress. Join your peers to address the unique challenges of rare renal drug development to spearhead novel therapeutics through to regulatory approval.

What Can You Expect for 2024?

Spanning discovery through to trial development and market access, this end-to-end summit will discuss challenges and opportunities from:

4th Rare & Genetic Kidney Disease Drug Development

Exploring molecular intricacies underlying disease pathophysiology

4th Rare & Genetic Kidney Disease Drug Development

Uncovering genetic study and -omic profiles to map response profiles and biomarkers

4th Rare & Genetic Kidney Disease Drug Development
4th Rare & Genetic Kidney Disease Drug Development

Evolving new strategies for patient identification using electronic health records, applying patient-centric outcome measures in trial design

Working with patients and associations as partners

Whether you’re entering the rare and genetic renal space or are a well-seasoned nephrology veteran, this forum will equip you with the know-how and connections to make rapid advances in your work.

2024 Expert Speakers Include

Previously Attending Companies Include:

MicrosoftTeams-image (15)

Testimonials:

vifor logo

 

"A good opportunity for scientists, drug developers and patient advocates to meet and discuss current issues in rare kidney diseases"

 

sanofi new

 

"The breadth across both preclinical and clinical hot topics was excellent, as was the quality of the speakers' presentations and the chairpersons' moderation"

 

Other Events in the Series: